The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, briefly discusses the importance of understanding the molecular mechanisms driving the transformation of indolent to aggressive lymphoid malignancies, including Richter’s transformation. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Transformation, histologic and clinical transformation from indolent to aggressive lymphoid malignancies still is a very important issue. Despite the pathway inhibitors in CLL, we still have Richter transformation which is very aggressive and it represents an unmet medical need. So understanding the molecular mechanisms is important and we have now several clues, for example, frequent activation of the myc proto-oncogene together with frequent disruption of TP53 genes and also loss of cell cycle inhibitors like CDKN2A, so all that helps us to understand, but also we know that a transformed clone may be present already, potentially even years or potentially even decades before the clinical transformation...
Transformation, histologic and clinical transformation from indolent to aggressive lymphoid malignancies still is a very important issue. Despite the pathway inhibitors in CLL, we still have Richter transformation which is very aggressive and it represents an unmet medical need. So understanding the molecular mechanisms is important and we have now several clues, for example, frequent activation of the myc proto-oncogene together with frequent disruption of TP53 genes and also loss of cell cycle inhibitors like CDKN2A, so all that helps us to understand, but also we know that a transformed clone may be present already, potentially even years or potentially even decades before the clinical transformation. So that poses for the future the idea of targeting very early Richter transformation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
